Beruflich Dokumente
Kultur Dokumente
T.B. Thomas*1, A.C. Morris*1, T.S. Nair1, B.M. Jewell1, H.M. Walline1, R.L. Delinger2, L.P. Campredon2, A.F. Brouwer2, M.C. Eisenberg2, R. Meza2, T.E. Carey1
1. Department of Otolaryngology, University of Michigan, Ann Arbor, MI 2. Department of Epidemiology, University of Michigan, Ann Arbor, MI
Figure 1: Follow-up data of study participants Figure 3: HPV prevalence in samples and individuals
Study visits completed per participant A All Samples HIV+ Samples HIV- Samples
Conclusions
300 274
Negative 658 Negative 112 Negative 546
• Recruitment has been successful, with many study participants
Positive 92 Positive 37 Positive 55
Number of Participants
250 returning for multiple additional visits. One participant has even
202 % HPV+ 12.3% % HPV+ 25.0% % HPV+ 9.2% come in for eight study visits.
200 • There is a statistically significant difference in HPV prevalence be
150
113
B All Individuals HIV+ Individuals HIV- Individuals
tween HIV+ samples and HIV-samples (p < 0.01).
• The difference in HPV prevalence is less drastic when assessing
100 74 Negative 382 Negative 88 Negative 294 individuals rather than samples, but still statistically significant (p
= 0.01).
50
42
27
Positive 83 Positive 30 Positive 53 • 17 different HPV types have been found in our study population.
14
1 % HPV+ 17.8% % HPV+ 25.4% % HPV+ 15.3% The three most common types (HPV18, HPV6, HPV16) make up
0
1 2 3 4 5 6 7 8 nearly half of all occurrences.
Study Visits Completed Figure 3A: The prevalence of HPV in samples for the two populations, sorted
by HIV status. There is a statistically significant difference in HPV prevalence
between HIV+ samples and HIV- samples (p < 0.01).
Figure 3B: The number of HPV+ and HPV- individuals found in our two popu- Acknowledgements
Figure 1: The number of study visits completed per participant. Study par- lations, sorted by HIV status. The difference in HPV prevalence is less drastic
ticipants visit every 3-4 months. Since this is an ongoing study, the de- when assessing individuals rather than samples, but still statistically signifi- • Sources of funding: NIH Grant U01CA182915,
creases in samples between study visits does not necessarily mean those cant (p = 0.01). Individuals are considered “positive” if they were HPV+ at NIH Grant P50DE019032
participants were lost to follow up. any point during their participation in the study. • We would like to thank our study participants.